Compare TG Therapeutics Inc (TGTX) vs State Street Real Estate Select Sector SPDR ETF (XLRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs State Street Real Estate Select Sector SPDR ETF — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while State Street Real Estate Select Sector SPDR ETF trades at $41.61 (market cap $7.61B). The key difference: TG Therapeutics Inc and State Street Real Estate Select Sector SPDR ETF are close in size by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, State Street Real Estate Select Sector SPDR ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and State Street Real Estate Select Sector SPDR ETF for 75 Days on average.
| TGTX | XLRE | |
|---|---|---|
Market Cap | $8.16B | $7.61B |
Volume | 1,735,121 | 7,876,569 |
Sector | Health | Sector/Thematic |
52-Week High | $59.06 | $46.01 |
52-Week Low | $26.94 | $40.01 |
Typical Hold Time | 16 Days | 75 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
XLRE trades at $40.85 with a modest 0.69% daily gain, though technical indicators signal a bearish trend with selling pressure outweighing buying signals 14-5. The ETF's low expense ratio of 0.08% and focus on 30 U.S. large-cap real estate holdings provide cost efficiency, while recent news highlights competition from digital infrastructure ETFs amid rising bond yields.
Outlook remains cautious due to bearish technicals and interest rate sensitivity, though the 3.2% dividend yield offers income appeal. Key risks include Fed policy volatility and sector rotation away from traditional REITs, requiring monitoring of macroeconomic shifts for potential rebound opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About State Street Real Estate Select Sector SPDR ETF
XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →
